Emergent BioSolutions Inc. (EBS)

Oncology Corporate Profile

Stock Performance

39.6400
-0.6100

3 Month Stock History Chart

HQ Location

2273 Research Boulevard, Suite 400
Rockville, MD 20850

Company Description

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders.

Website: http://www.emergentbiosolutions.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
otlertuzumabCD37 protein inhibitor)Chronic Lymphocytic Leukemia (CLL)II
TRU-016 (+ bendamustine)anti-CD37 IgG fusion proteinNon-Hodgkins Lymphoma (NHL)II
HuMax-CD4® / zanolimumabimmunosuppressiveCutaneous T-cell Lymphoma (CTCL)I
HuMax-CD4® / zanolimumabimmunosuppressivePeripheral T-cell Lymphoma (PTCL)I
MOR209/ES414anti-PSMA/anti-CD3 bi-specific antibodyProstate cancerPreclinicalMorphosys

View additional information on product candidates here »

Source: http://www.emergentbiosolutions.com/

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/14/2017 06:18 am

8/13/2017 06:18 am

8/11/2017 06:18 am

8/11/2017 06:18 am

8/11/2017 06:18 am

8/11/2017 06:18 am

8/10/2017 06:18 am

8/10/2017 06:18 am

8/10/2017 06:18 am

8/10/2017 06:18 am

8/10/2017 06:18 am

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/7/2017 06:18 pm

8/4/2017 12:18 pm

8/4/2017 12:18 am

8/3/2017 12:18 pm

8/1/2017 12:18 pm